RECOMBINANT ADENOVIRUSES WITH LARGE DELETIONS GENERATED BY CRE-MEDIATED EXCISION EXHIBIT DIFFERENT BIOLOGICAL PROPERTIES COMPARED WITH FIRST-GENERATION VECTORS IN-VITRO AND IN-VIVO
A. Lieber et al., RECOMBINANT ADENOVIRUSES WITH LARGE DELETIONS GENERATED BY CRE-MEDIATED EXCISION EXHIBIT DIFFERENT BIOLOGICAL PROPERTIES COMPARED WITH FIRST-GENERATION VECTORS IN-VITRO AND IN-VIVO, Journal of virology, 70(12), 1996, pp. 8944-8960
In vivo gene transfer of recombinant E1-deficient adenoviruses results
in early and late viral gene expression that elicits a host immune re
sponse, limiting the duration of transgene expression and the use of a
denoviruses for gene therapy. The prokaryotic Cre-lox P recombination
system was adapted to generate recombinant adenoviruses with extended
deletions in the viral genome (referred to here as deleted viruses) in
order to minimize expression of immunogenic and/or cytotoxic viral pr
oteins. As an example, an adenovirus with a 25-kb deletion that lacked
E1, E2, E3, and late gene expression with viral titers similar to tho
se achieved with first-generation vectors and less than 0.5% contamina
tion with E1-deficient virus was produced. Gene transfer was similar i
n HeLa cells, mouse hepatoma cells, and primary mouse hepatocytes in v
itro and in vivo as determined by measuring reporter gene expression a
nd DNA transfer. However, transgene expression and deleted viral DNA c
oncentrations were not stable and declined to undetectable levels much
more rapidly than those found for first generation vectors. Intraveno
us administration of deleted vectors in mice resulted in no hepatocell
ular injury relative to that seen with first-generation vectors. The m
echanism for stability of first-generation adenovirus vectors (E1a del
eted) appeared to be linked in part to their ability to replicate in t
ransduced cells in vivo and in vitro. Furthermore, the deleted vectors
were stabilized in the presence of undeleted first-generation adenovi
rus vectors. These results have important consequences for the develop
ment of these and other nonintegrating vectors for gene therapy.